Late stage development of two first-in-category wound care products Stockholm, February 2020
Disclaimer Impo Important ant infor informat mation ion You must read the following before continuing. The following applies to this document and the information provided in this prese ntation by Promore Pharma AB (publ) (the “ Company ”) or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the “ Information ”), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions. The Information does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (th e “ Securities Ac t”), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States absent registration under the Securities Act or exemption from the registration requirement thereof. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities referred to herein cannot be offered, sold, pledged or otherwise transferred, directly or indirectly, within or into the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. This presentation does not constitute a “prospectus” within the meaning of the Securities Act or the Swedish Financial Instruments Trading Act. This presentation is only being provided to persons that are (i) “Qualified Institutional Buyers”, as defined in Rule 144A under the U.S. Securities Act, or (ii) outside the United States. B y attending this presentation or by reading the presentation slides, you warrant and acknowledge that you fall within one of the categories (i) and (ii) above. Any securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan and may not be offered or sold within Canada, Australia or Japan or to any national, resident or citizen of Canada, Australia or Japan. All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company’s operations, financial position and earnings. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “e sti mates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to ident ify forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it though t would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. 2
Management Team Jonas s Ekb Ekblom, lom, CE CEO Margit it Mahla lapuu, , CSO CSO Jenni i Björ Björnulfson lfson, , CF CFO ▪ Over 25 years of experience from the life science ▪ Close to 20 years of experience in discovery and ▪ More than 15 years of experience from the sector, with a focus in pharmacology and drug development of novel pharmaceuticals from the financial markets with a strong focus on the health development. biotech and pharma industry. care sector. Worked both with Corporate finance and equities research. Also management ▪ Experience from Bows Pharmaceuticals AG, ▪ Experience from Arexis, AstraZeneca, Biovitrum experience from health care services. Pharmacia, Biovitrum, Sequenom and Invitrogen ▪ Authored 50 articles in peer-reviewed scientific (now Thermo Fischer) ▪ Experience from Handelsbanken Markets, Alfred journals and inventor on 7 pending patent Berg/ABN AMRO, S&P, ABG Sundal Collier, GHP applications. Professor in Molecular Medicine at ▪ Ekblom has published over 60 peer-reviewed articles Sahlgrenska Academy ▪ Joined 2016 ▪ Joined 2010 ▪ Joined 2007 3
Promore Pharma in Brief Two late stage, first-in-category products ▪ Human peptides for local administration with extraordinary safety ▪ Phase IIb – LL-37 Phase III – PXL01 ▪ Treating chronic wounds, mainly ▪ Preventing adhesions after tendon VLUs repair surgery No prescription drugs ▪ No prescription drugs ▪ 6 million patients in EU, NA & JP ▪ 1 million patients in EU, NA & JP ▪ ▪ Addressable global market 3 BUSD ▪ Addressable EU market 300 MUSD ▪ Indication broadening opportunities ▪ Indication broadening opportunities Vision To solve the global problems of scarring, adhesions and chronic wounds 4
Summary 2019 – Operational Goals 2020 Continuous improvements in supply chain have • ✓ • Phase III trial with PXL01 modified and the been made number of clinics expanded Convinced that IMP soon can be produced for • trial and recruitment could start in 2020. However, additional funding required. ✓ Kerstin Valinder Strinnholm elected • • Strong business development experience from member of the Board of Directors pharma industry added HEAL LL-37 recruitment completed. Half of • • Recruitment completed ahead of schedule ✓ the patients recruited in June. • Data available in Q4 2020 • Patent granted for LL-37 in Japan and for ✓ • Improving our strong IP position PXL01 in USA ✓ Funding secured for finalizing HEAL LL-37 and • Rights issue completed • PHSU03 preparations ✓ Liquidity provider engaged • • Important step for correct valuation and improved shareholder structure 5
Local Delivery of Peptides: The Way to Go BIO BIOAVAIL AILABIL ILIT ITY Drug available at site of action in a medically relevant amount DURA DURATI TION Temporal exposure can readily be controlled through choice of formulation DOSING DOSI Flexible dosing by choice of injection volume SAFETY SAFE TY Rapid degradation of peptides in the bloodstream: very low systemic exposure 6
LL-37
LL-37: Treatment of Chronic Wounds Medical Need and Costs for Society Promore Pharma and LL-37 ▪ >15 million patients with challenging ▪ Naturally occurring peptide (cathelicidin) wounds on the major pharmaceutical Antimicrobial – markets Angiogenic – Stimulates keratinocyte migration – VLUs LL-37 involved in wound biology ▪ DFUs ▪ Present in acute wounds but not in chronic Pus wounds Other First indication VLUs ▪ ▪ Largest patient population in major ▪ Very few prescription products pharmaceutical markets Some available for DFUs, but all with ▪ ▪ No pharmaceuticals available limited medical value ▪ Not as complicated from a development ▪ Low R&D competition perspective Costs for treating chronic wounds exceed ▪ All chronic wounds could potentially be ▪ 10,000 USD per episode addressed with LL-37 8
Recommend
More recommend
